Leidos Holdings Inc (Leidos) is a provider of technology services and solutions to the defense, civil, intelligence, and health markets. It serves the Department of Defense (DoD), commercial businesses, and local and state government agencies. As of December 2023, Leidos had operations in 427 locations in 44 states, the District of Columbia, and foreign countries.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Leidos conducts research and development activities under customer-funded contracts and with company-funded research and development funds. The company's R&D includes independent research and development (IR&D) and commercial and international research and development. Leidos Holdings provides life science research and development support to the NIH, Center for Disease Control, Army Medical Research community, and commercial biotech companies. The company operates the Frederick National Laboratory for Cancer Research on behalf of the U.S. government and the public trust. It operates a wide range of research and development laboratories in the areas of genetics and genomics, proteins and proteomics, advanced biomedical computing and information technology, biopharmaceutical development and manufacturing, nanotechnology characterization, and clinical trials management. In FY2023, the company incurred expenses of US$128 million on R&D, which as a percentage of revenue, stood at 0.8%.